Sagimet Biosciences Inc. (SGMT)
SGMT Stock Price Chart
Explore Sagimet Biosciences Inc. interactive price chart. Choose custom timeframes to analyze SGMT price movements and trends.
SGMT Company Profile
Discover essential business fundamentals and corporate details for Sagimet Biosciences Inc. (SGMT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
14 Jul 2023
Employees
16.00
Website
https://www.sagimet.comCEO
David Happel
Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
SGMT Financial Timeline
Browse a chronological timeline of Sagimet Biosciences Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.28.
Earnings released on 12 May 2026
EPS came in at -$0.33 surpassing the estimated -$0.39 by +15.38%.
Earnings released on 11 Mar 2026
EPS came in at -$0.29 surpassing the estimated -$0.43 by +32.56%.
Earnings released on 13 Nov 2025
EPS came in at -$0.40 surpassing the estimated -$0.41 by +2.44%.
Earnings released on 13 Aug 2025
EPS came in at -$0.32 surpassing the estimated -$0.52 by +38.46%.
Earnings released on 8 May 2025
EPS came in at -$0.56 surpassing the estimated -$0.79 by +29.11%.
Earnings released on 12 Mar 2025
EPS came in at -$0.50 surpassing the estimated -$0.65 by +23.08%.
Earnings released on 14 Nov 2024
EPS came in at -$0.45 surpassing the estimated -$0.47 by +4.26%.
Earnings released on 14 Aug 2024
EPS came in at -$0.25 surpassing the estimated -$0.34 by +26.47%.
Earnings released on 15 May 2024
EPS came in at -$0.23 surpassing the estimated -$0.41 by +43.90%.
Earnings released on 25 Mar 2024
EPS came in at -$0.78 falling short of the estimated -$0.58 by -34.48%.
Earnings released on 13 Nov 2023
EPS came in at -$0.35 surpassing the estimated -$1.02 by +65.69%, while revenue for the quarter reached $2.00m .
Earnings released on 14 Jul 2023
EPS came in at -$35.80 falling short of the estimated -$0.50 by -7.06k%.
Earnings released on 31 Mar 2023
EPS came in at -$0.30 .
Earnings released on 31 Dec 2022
EPS came in at -$0.32 .
Earnings released on 30 Sept 2022
EPS came in at -$0.34 .
Earnings released on 30 Jun 2022
EPS came in at -$0.32 .
Earnings released on 31 Mar 2022
EPS came in at -$0.39 .
SGMT Stock Performance
Access detailed SGMT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
